John E. Heath

John E. Heath

Auto-generated profile, based on publicly available information

John E. Heath

Department of Bioengineering, Stanford University, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Cell
Verified
Journal Article
Open access
YSYapeng Su
Yapeng Su
DCDaniel Guorui Chen
Daniel Guorui Chen
DYDan Yuan
Dan Yuan
CLChristopher Lausted
Christopher Lausted
JCJongchan Choi
Jongchan Choi
JHJames R. Heath
James R. Heath
We present an integrated analysis of the clinical measurements, immune cells, and plasma multi-omics of 139 COVID-19 patients representing all levels of disease severity, from serial blood draws collected during the first week of infection following diagnosis. We identify a major shift between mild and moderate disease, at which point elevated inflammatory signaling is accompanied by the loss of specific classes of metabolites and metabolic processes. Within this stressed plasma environment at moderate disease, multiple unusual immune cell phenotypes emerge and amplify with increasing disease severity. We condensed over 120,000 immune features into a single axis to capture how different immune cell classes coordinate in response to SARS-CoV-2. This immune-response axis independently aligns with the major plasma composition changes, with clinical metrics of blood clotting, and with the sharp transition between mild and moderate disease. This study suggests that moderate disease may provide the most effective setting for therapeutic intervention.

1 September 2019 in Cell Reports
Verified
Journal Article
Open access
SPSongming Peng
Songming Peng
JZJesse M. Zaretsky
Jesse M. Zaretsky
ANAlphonsus H.C. Ng
Alphonsus H.C. Ng
WCWilliam Chour
William Chour
MBMichael T. Bethune
Michael T. Bethune
JHJames R. Heath
James R. Heath
Neoantigen-specific T cells are increasingly viewed as important immunotherapy effectors, but physically isolating these rare cell populations is challenging. Here, we describe a sensitive method for the enumeration and isolation of neoantigen-specific CD8+ T cells from small samples of patient tumor or blood. The method relies on magnetic nanoparticles that present neoantigen-loaded major histocompatibility complex (MHC) tetramers at high avidity by barcoded DNA linkers. The magnetic particles provide a convenient handle to isolate the desired cell populations, and the barcoded DNA enables multiplexed analysis. The method exhibits superior recovery of antigen-specific T cell populations relative to literature approaches. We applied the method to profile neoantigen-specific T cell populations in the tumor and blood of patients with metastatic melanoma over the course of anti-PD1 checkpoint inhibitor therapy. We show that the method has value for monitoring clinical responses to cancer immunotherapy and might help guide the development of personalized mutational neoantigen-specific T cell therapies and cancer vaccines.

10 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
HLHongyi R. Li
Hongyi R. Li
MHManwal Harb
Manwal Harb
JHJohn E. Heath
John E. Heath
JTJames S. Trippett
James S. Trippett
MSMikhail G. Shapiro
Mikhail G. Shapiro
JSJerzy O. Szablowski
Jerzy O. Szablowski
Targeted gene delivery to the brain is a critical tool for neuroscience research and has significant potential to treat human disease. However, the site-specific delivery of common gene vectors such as adeno-associated viruses (AAVs) is typically performed via invasive injections, which limit its applicable scope of research and clinical applications. Alternatively, focused ultrasound blood-brain-barrier opening (FUS-BBBO), performed noninvasively, enables the site-specific entry of AAVs into the brain from systemic circulation. However, when used in conjunction with natural AAV serotypes, this approach has limited transduction efficiency and results in substantial undesirable transduction of peripheral organs. Here, we use high throughput in vivo selection to engineer new AAV vectors specifically designed for local neuronal transduction at the site of FUS-BBBO. The resulting vectors substantially enhance ultrasound-targeted gene delivery and neuronal tropism while reducing peripheral transduction, providing a more than ten-fold improvement in targeting specificity in two tested mouse strains. In addition to enhancing the only known approach to noninvasively target gene delivery to specific brain regions, these results establish the ability of AAV vectors to be evolved for specific physical delivery mechanisms.

6 July 2018 in Analytical Chemistry
Verified
Journal Article
Closed access
AMAmy M. McCarthy
Amy M. McCarthy
JKJungwoo Kim
Jungwoo Kim
AMA. Katrine Museth
A. Katrine Museth
RHRyan K. Henning
Ryan K. Henning
JHJohn E. Heath
John E. Heath
JHJames R. Heath
James R. Heath

17 September 2015 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
SDSamir Das
Samir Das
ANArundhati Nag
Arundhati Nag
JLJingXin Liang
JingXin Liang
DBDavid N. Bunck
David N. Bunck
AUAiko Umeda
Aiko Umeda
JHJames R. Heath
James R. Heath

27 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
HLHongyi Li
Hongyi Li
JHJohn E. Heath
John E. Heath
JTJames S. Trippett
James S. Trippett
MSMikhail G. Shapiro
Mikhail G. Shapiro
JSJerzy O. Szablowski
Jerzy O. Szablowski
Targeted gene delivery to the brain is a critical tool for neuroscience research and has significant potential to treat human disease. However, the site-specific delivery of common gene vectors such as adeno-associated viruses (AAVs) is typically performed via invasive injections, limiting their scope of research and clinical applications. Alternatively, focused ultrasound blood-brain-barrier opening (FUS-BBBO), performed noninvasively, enables the site-specific entry of AAVs into the brain from systemic circulation. However, when used in conjunction with natural AAV serotypes, this approach has limited transduction efficiency, requires ultrasound parameters close to tissue damage limits, and results in undesirable transduction of peripheral organs. Here, we use high throughput in vivo selection to engineer new AAV vectors specifically designed for local neuronal transduction at the site of FUS-BBBO. The resulting vectors substantially enhance ultrasound-targeted gene delivery and neuronal tropism while reducing peripheral transduction, providing a more than ten-fold improvement in targeting specificity. In addition to enhancing the only known approach to noninvasively target gene delivery to specific brain regions, these results establish the ability of AAV vectors to be evolved for specific physical delivery mechanisms.